Determination Phase 3 Trial: RVd Alone Versus Rvd Plus Autologous Stem Cell Transplantation in Newly Diagnosed African American Patients
Dr. Paul G. Richardson reports on the use of RvD alone versus RvD alongside an autologous stem cell transplantation (ASCT) in the treatment of newly diagnosed multiple myeloma.
Abstract Title:
Treatment Outcomes and Prognostic Factors with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in African American (AA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial
What is the purpose of this trial?
The purpose of the trial is to The purpose of the study was to compare treatment outcomes and prognostic factors in African American (AA) patients with newly diagnosed multiple myeloma (NDMM) who received lenalidomide, bortezomib, and dexamethasone (RVd) alone versus RVd plus autologous stem cell transplantation (ASCT). Previous research indicated that AA patients may have equal or longer overall survival (OS) compared to White patients when treatment access is equal, but the specific impact of different treatment approaches on AA patients was not well understood. The study, known as Determination, aimed to provide insights into this by analyzing progression-free survival (PFS), event-free survival (EFS), overall survival (OS), and safety outcomes in AA patients receiving either RVd alone or RVd+ASCT.
In this video:
Pau G. Richardson, MD, (Dana-Farber Cancer Institute — Boston, MA) reports on treatment outcomes and prognostic factors with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in African American patients with newly diagnosed multiple myeloma (NDMM).
Conclusion:
From the abstract: “Our analyses suggest that PFS, EFS, and OS were similar with RVd-alone and RVd+ASCT in AA pts on this study. Importantly, while outcomes with RVd+ASCT were similar in AA and White pts, exploratory analyses suggest AA pts with high BMI and female AA pts may derive more PFS benefit from RVd-alone. Rates of starting maintenance/NPT use were lower in AA vs White pts, but maintenance duration proved longer in AA pts, with similar rates of grade ≥3 hematologic AEs, including neutropenia; analyses of outcomes by Duffy status are ongoing and will be presented."
Trial Information: Abstract #4762
Doctor Bio:
Paul G. Richardson, MD, received certifications in Internal Medicine, Hematology, and Medical Oncology. Joining the Jerome Lipper Myeloma Center in 1999, Dr. Richardson eventually became the Clinical Director in 2001. His pivotal contributions include leading the development of groundbreaking drugs such as Velcade® (bortezomib), Revlimid® (lenalidomide), and Pomalyst® (pomalidomide) for the treatment of multiple myeloma. Over the years, he has focused on next-generation novel drugs, exploring compounds like panobinostat and second-generation proteasome inhibitors, including Ninlaro® (ixazomib).
Dr. Richardson's recent endeavors have centered on pioneering monoclonal antibodies like Empliciti™ (elotuzumab) and Darzalex® (daratumumab), as well as advancing antibody drug conjugates, including Blenrep® (belantamab mafodotin), and other innovative immunotherapeutic strategies. Notable contributions include his leadership in the development of melflufen, a targeted cytotoxic; and the groundbreaking small molecule inhibitor Xpovio® (selinexor), targeting the key protein XPO-1. He is also at the forefront of research on cereblon E3 ligase modulators (CELMoDs) for relapsed and refractory myeloma.
With an extensive publication record comprising over 400 original articles and 330 reviews, chapters, and editorials in peer-reviewed journals, Dr. Richardson has established himself as a leading figure in the field. His leadership roles in organizations such as the Multiple Myeloma Research Consortium (MMRC) and the Alliance Myeloma Committee underscore his commitment to collaborative research. Among numerous awards, he was also the 2017 recipient of the IMF’s Robert A. Kyle Lifetime Achievement Award.
